Dr. Herzog on the FDA Approval of Olaparib/Bevacizumab as Frontline Maintenance in Ovarian Cancer

Updates in Ovarian Cancer: Frontline MaintenanceПодробнее

Dr. Herzog on the Optimal Use of Bevacizumab in Patients With Ovarian CancerПодробнее

Dr. Willmott on FDA Approval of Maintenance Olaparib in Ovarian CancerПодробнее

Maintenance Therapy in Ovarian CancerПодробнее

Frontline Bevacizumab Strategies in Ovarian CancerПодробнее

Biomarker-Driven Frontline Ovarian Cancer TreatmentПодробнее

PARP + Maintenance Bevacizumab in Ovarian CancerПодробнее

Dr. Arend on FDA Approval of Frontline Bevacizumab in Ovarian CancerПодробнее

Upfront Bevacizumab in Advanced Ovarian CancerПодробнее

Final OS results from PAOLA-1 evaluating 1L maintenance olaparib plus bevacizumabПодробнее

Bevacizumab in Recurrent Ovarian CancerПодробнее

Front Line Treatment of Ovarian Cancer Dr. Thomas HerzogПодробнее

Dr. Hardesty on Bevacizumab/PARP Inhibitor Combination in Ovarian CancerПодробнее

Ovarian Cancer: Maintenance Following Frontline BevacizumabПодробнее

Implications of PAOLA-1 in Advanced Ovarian CancerПодробнее

Updates on Frontline Treatment of Ovarian Cancer Dr. Thomas Herzog (Day1) 2021Подробнее

The Impact of PAOLA-1 on Frontline Treatment of Ovarian CancerПодробнее

SOLO-1: Frontline Olaparib Maintenance Therapy in Ovarian CancerПодробнее

The PAOLA-1 study: olaparib and bevacizumab for ovarian cancerПодробнее